A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

NCT06256328 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: ONO-4578
DRUG: Oxaliplatin
DRUG: Capecitabine
DRUG: S-1
DRUG: Nivolumab
DRUG: Placebo

Sponsor

Ono Pharmaceutical Co., Ltd.